NCT05179603View on ClinicalTrials.gov

A Study of SAR444245 With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma (Master Protocol) [Pegathor Lymphoma 205]

PHASE2TerminatedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

December 7, 2021

Primary Completion Date

September 14, 2023

Study Completion Date

September 6, 2024

Conditions
Classic Hodgkin LymphomaDiffuse Large B-cell Lymphoma
Interventions
DRUG

THOR-707

Pharmaceutical Form: Solution for infusion Route of Administration: Intravenous infusion

DRUG

Pembrolizumab

Pharmaceutical Form: Solution for infusion Route of Administration: Intravenous infusion

Trial Locations (8)

1430

Investigational Site Number : 0320005, CABA

28040

Investigational Site Number : 7240004, Madrid / Madrid

2540488

Investigational Site Number : 1520004, Viña del Mar

4800827

Investigational Site Number : 1520001, Temuco

7500653

Investigational Site Number : 1520003, Santiago

7500921

Investigational Site Number : 1520002, Santiago

08036

Investigational Site Number : 7240002, Barcelona

08908

Investigational Site Number : 7240001, L'Hospitalet de Llobregat

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Sanofi

INDUSTRY

NCT05179603 - A Study of SAR444245 With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma (Master Protocol) [Pegathor Lymphoma 205] | Biotech Hunter | Biotech Hunter